Search research articles
Contact Us
Filters
Showing results (71-80 of 123) with videos related to
Page
of 13
Sort By:
Journal of Hematology & Oncology
|
January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Leukemia Research
|
October 16, 2018
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Haematologica
|
April 7, 2018
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora, Toni Giorgino, Paola Guglielmelli, et al.
Hematological Oncology
|
February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients
Giulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hematological Oncology
|
April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Journal of Cancer Research and Clinical Oncology
|
April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Chiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
American Journal of Hematology
|
October 8, 2019
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group
Barbara Mora, Paola Guglielmelli, Elisa Rumi, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 123) with videos related to
Sort By:
Page
of 13
Journal of Hematology & Oncology
|
January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Leukemia Research
|
October 16, 2018
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Haematologica
|
April 7, 2018
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora, Toni Giorgino, Paola Guglielmelli, et al.
Hematological Oncology
|
February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients
Giulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hematological Oncology
|
April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Journal of Cancer Research and Clinical Oncology
|
April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Chiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
American Journal of Hematology
|
October 8, 2019
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group
Barbara Mora, Paola Guglielmelli, Elisa Rumi, et al.
Page
of 13